Dantrolene as a possible prophylactic treatment for RYR1-related rhabdomyolysis

European Journal of Neurology

Volumn 23, Issue 8, 2016, Pages e56-e57

  Scalco, R S ^a   Voermans, N C ^b   Piercy, R J ^c   Jungbluth, H ^d   Quinlivan, R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ROYAL VETERINARY COLLEGE   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

dantrolene; myoglobinuria; rhabdomyolysis prophylaxis; rhabdomyolysis treatment; RYR1; RYR1 dantrolene; RYR1 prophylaxis; RYR1 treatment

Indexed keywords

CAFFEINE; CREATINE KINASE; DANTROLENE; RYANODINE RECEPTOR 1;

ADULT; ANXIETY; CASE REPORT; COFFEE; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; ENVIRONMENTAL TEMPERATURE; EXERCISE; FEMALE; FOLLOW UP; GENETIC VARIATION; HUMAN; HUMAN TISSUE; INTENSIVE CARE; INTENSIVE CARE UNIT; LEG PAIN; LETTER; MALE; MUSCLE BIOPSY; MUSCLE CRAMP; MYALGIA; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROPHYLAXIS; RHABDOMYOLYSIS; SLEEP DEPRIVATION; SOFT DRINK; VIRUS INFECTION;

EID: 84978481274     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.13051     Document Type: Letter

References (11)

1. Scalco RS, Gardiner AR, Pitceathly RD, et al. Rhabdomyolysis: a genetic perspective. Orphanet J Rare Dis 2015; 10: 51.
2. Dlamini N, Voermans NC, Lillis S, et al. Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis. Neuromuscul Disord 2013; 23: 540–548.
3. Jungbluth H, Dowling JJ, Ferreiro A, Muntoni F. 182nd ENMC International Workshop: RYR1-related myopathies, 15–17th April 2011, Naarden, The Netherlands. Neuromuscul Disord 2012; 22: 453–462.
4. Snoeck M, Treves S, Molenaar JP, Kamsteeg EJ, Jungbluth H, Voermans NC. “Human Stress Syndrome” and the expanding spectrum of RYR1-related myopathies. Cell Biochem Biophys 2016; 74: 85–87.
5. Butala BN, Kang A, Guron J, Brandom BW. Long term oral dantrolene improved muscular symptoms in a malignant hyperthermia susceptible individual. J Neuromuscul Dis 2016; 3: 115–119.
6. McKenzie EC, Valberg SJ, Godden SM, Finno CJ, Murphy MJ. Effect of oral administration of dantrolene sodium on serum creatine kinase activity after exercise in horses with recurrent exertional rhabdomyolysis. Am J Vet Res 2004; 65: 74–79.
7. Edwards JG, Newtont JR, Ramzan PH, Pilsworth RC, Shepherd MC. The efficacy of dantrolene sodium in controlling exertional rhabdomyolysis in the Thoroughbred racehorse. Equine Vet J 2003; 35: 707–711.
8. Dranchak PK, Valberg SJ, Onan GW, et al. Exclusion of linkage of the RYR1, CACNA1S, and ATP2A1 genes to recurrent exertional rhabdomyolysis in Thoroughbreds. Am J Vet Res 2006; 67: 1395–1400.
9. Lentz LR, Valberg SJ, Balog EM, Mickelson JR, Gallant EM. Abnormal regulation of muscle contraction in horses with recurrent exertional rhabdomyolysis. Am J Vet Res 1999; 60: 992–999.
10. Fernandez-Fuente M, Terracciano CM, Martin-Duque P, Brown SC, Vassaux G, Piercy RJ. Calcium homeostasis in myogenic differentiation factor 1 (MyoD)-transformed, virally-transduced, skin-derived equine myotubes. PLoS ONE 2014; 9: e105971.
11. Court MH, Engelking LR, Dodman NH, Anwer MS, Seeler DC, Clark M. Pharmacokinetics of dantrolene sodium in horses. J Vet Pharmacol Ther 1987; 10: 218–226.